Top

Published in:

01-11-2007 | Research Paper

Soluble cadherins as cancer biomarkers

Authors: Olivier De Wever, Lara Derycke, An Hendrix, Gert De Meerleer, François Godeau, Herman Depypere, Marc Bracke

Published in: Clinical & Experimental Metastasis | Issue 8/2007

Abstract

Molecular activities, regulating a balanced tissue organisation, are frequently disturbed during cancer progression. These include protein ectodomain shedding, a post-translational process that substantially changes the functional properties of the substrate protein. In comparison with normal epithelia, cancer cells almost invariably show diminished cadherin-mediated intercellular adhesion. This review will address cadherin ectodomain shedding and its functional consequence in normal physiology and in the tumor environment. Soluble cadherin fragments may retain specific biological activities during cancer cell invasion, angiogenesis and perineural invasion. When diffusion barriers disappear, soluble cadherins are detected in sera from cancer patients. Soluble N-(neural) cadherin may represent a novel diagnosis/prognostic biomarker showing a correlation with PSA in sera of prostate cancer patients. Furthermore, therapeutic monitoring in pancreas adenomacarcinoma revealed a correlation between circulating soluble N-cadherin and CA 19-9. A better understanding of cadherin regulation in cancer progression will likely increase our awareness of the importance of the combinatorial signals that regulate tissue integrity and eventually result in the identification of new therapeutics targeting cadherins.

Gupta GP, Massagué J (2006) Cancer metastasis: building a framework. Cell 127:679–695PubMedCrossRef

Van Aken E, De Wever O, Correia da Rocha AS, Mareel M (2001) Defective E-cadherin/catenin complexes in human cancer. Virchows Arch 439:725–751PubMed

De Wever O, Mareel M (2003) Role of tissue stroma in cancer cell invasion. J Pathol 200:429–447PubMedCrossRef

Blobel CP (2005) ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 6:32–43PubMedCrossRef

Seals DF, Courtneidge SA (2003) The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 17:7–30PubMedCrossRef

Levi E, Fridman R, Miao H-Q et al (1996) Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA 93:7069–7074PubMedCrossRef

Vecchi M, Rudolph-Owen LA, Brown CL et al (1998) Tyrosine phosphorylation and proteolysis. Pervanadate-induced, metalloprotease-dependent cleavage of the ErbB-4 receptor and amphiregulin. J Biol Chem 273:20589–20595PubMedCrossRef

Codony-Servat J, Albanell J, Lopez-Talavera JC et al (1999) Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 59:1196–1201PubMed

Nath D, Williamson NJ, Jarvis R, Murphy G (2001) Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J Cell Sci 114:1213–1220PubMed

10.

Cavallaro U et al (2004) N-cadherin as an invasion promoter: a novel target for antitumor therapy? Curr Opin Investig Drugs 5:1274–1278PubMed

11.

Noë V, Fingleton B, Jacobs K et al (2001) Release of an invasion promotor E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114:111–118PubMed

12.

Damsky CH, Richa J, Solter D et al (1983) Identification and purification of a cell surface glycoprotein mediating intercellular adhesion in embryonic and adult tissue. Cell 34:455–466PubMedCrossRef

13.

Wheelock MJ, Buck CA, Bechtol KB, Damsky CH (1987) Soluble 80-kd fragment of cell-CAM 120/80 disrupts cell-cell adhesion. J Cell Biochem 34:187–202PubMedCrossRef

14.

Symowicz J, Adley BP, Gleason KJ et al (2007) Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res 67:2030–2039PubMedCrossRef

15.

Davies G, Jiang WG, Mason MD (2001) Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion. Clin Cancer Res 7:3289–3297PubMed

16.

Ryniers F, Stove C, Goethals M et al (2002) Plasmin produces an E-cadherin fragment that stimulates cancer cell invasion. Biol Chem 383:159–165PubMedCrossRef

17.

Hayashido Y, Hamana T, Yoshioka Y et al (2005) Plasminogen activator/plasmin system suppresses cell-cell adhesion of oral squamous cell carcinoma cells via proteolysis of E-cadherin. Int J Oncol 27:693–698PubMed

18.

Johnson SK, Ramani VC, Hennings L, Haun RS (2007) Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin. Cancer 109:1811–1820PubMedCrossRef

19.

Covington MD, Burghardt RC, Parrish AR et al (2006) Ischemia-induced cleavage of cadherins in NRK cells requires MT1-MMP (MMP-14). Am J Physiol Renal Physiol 290:F43–F51PubMedCrossRef

20.

Maretzky T, Reiss K, Ludwig A et al (2005) ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and β-catenin translocation. Proc Natl Acad Sci USA 102:9182–9187PubMedCrossRef

21.

Steinhusen U, Weiske J, Badock V et al (2001) Cleavage and shedding of E-cadherin after induction of apoptosis. J Biol Chem 276:4972–4980PubMedCrossRef

22.

Rashid MG, Sanda MG, Vallorosi CJ et al (2001) Posttranslational truncation and inactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate. Cancer Res 61:489–492PubMed

23.

Rios-Doria J, Day KC, Kuefer R et al (2003) The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. J Biol Chem 278:1372–1379PubMedCrossRef

24.

Reiss K, Maretzky T, Ludwig A et al (2005) ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and β-catenin nuclear signalling. EMBO J 24:742–752PubMedCrossRef

25.

Monea S, Jordan BA, Srivastava S et al (2006) Membrane localization of membrane type 5 matrix metalloproteinase by AMPA receptor binding protein and cleavage of cadherins. J Neurosci 26:2300–2312PubMedCrossRef

26.

Uemura K, Kihara T, Kuzuya A et al (2006) Characterization of sequential N-cadherin cleavage by ADAM10 and PS1. Neurosci Lett 402:278–283PubMedCrossRef

27.

Paradies NE, Grunwald GB (1993) Purification and characterization of NCAD90, a soluble endogenous form of N-cadherin, which is generated by proteolysis during retinal development and retains adhesive and neurite-promoting function. J Neurosci Res 36:33–45PubMedCrossRef

28.

Marambaud P, Wen PH, Dutt A et al (2003) A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell 114:635–645PubMedCrossRef

29.

Shoval I, Ludwig A, Kalcheim C (2007) Antagonistic roles of full-length N-cadherin and its soluble BMP cleavage product in neural crest delamination. Development 134:491–501PubMedCrossRef

30.

Tai C-Y, Mysore SP, Chiu C, Schuman EM (2007) Activity-regulated N-cadherin endocytosis. Neuron 54:771–785PubMedCrossRef

31.

Uemura K, Kuzuya A, Aoyagi N et al (2007) Amyloid β inhibits ectodomain shedding of N-cadherin via down-regulation of cell-surface NMDA receptor. Neuroscience 145:5–10PubMedCrossRef

32.

Noë V, Willems J, Vandekerckhove J et al (1999) Inhibition of adhesion and induction of epithelial cell invasion by HAV-containing E-cadherin-specific peptides. J Cell Sci 112:127–135PubMed

33.

Nawrocki-Raby B, Gilles C, Polette M et al (2003) Upregulation of MMPs by soluble E-cadherin in human lung tumor cells. Int J Cancer 105:790–795PubMedCrossRef

34.

Lee KH, Choi EY, Hyun MS et al (2007) Association of extracellular cleavage of E-cadherin mediated by MMP-7 with HGF-induced in vitro invasion in human stomach cancer cells. Eur Surg Res 39:208–215PubMedCrossRef

35.

Derycke L, Morbidelli L, Ziche M et al (2006) Soluble N-cadherin fragment promotes angiogenesis. Clin Exp Metastasis 23:187–201PubMedCrossRef

36.

De Wever O, Westbroek W, Verloes A et al (2004) Critical role of N-cadherin in myofibroblast invasion and migration in vitro stimulated by colon-cancer-cell-derived TGF-β or wounding. J Cell Sci 117:4691–4703PubMedCrossRef

37.

Utton MA, Eickholt B, Howell FV et al (2001) Soluble N-cadherin stimulates fibroblast growth factor receptor dependent neurite outgrowth and N-cadherin and the fibroblast growth factor receptor co-cluster in cells. J Neurochem 76:1421–1430PubMedCrossRef

38.

Cifuentes-Diaz C, Nicolet M, Goudou D et al (1994) N-cadherin expression in developing, adult and denervated chicken neuromuscular system: accumulations at both the neuromuscular junction and the node of Ranvier. Development 120:1–11PubMed

39.

Whittard JD, Craig SE, Mould AP et al (2002) E-cadherin is a ligand for integrin α2ß1. Matrix Biol 21:525–532PubMedCrossRef

40.

De Wever O, Mareel M (2006) Pro-invasive molecular cross-signaling between cancer cells and myofibroblasts. In: Chaponnier C, Desmoulière A, Gabbiani G (eds) Tissue Repair, Contraction and the Myofibroblast, Chapt. 8. Eurekah.com and Springer Science+Business Media, pp 74–87

41.

De Wever O, Nguyen Q-D, Van Hoorde L et al (2004) Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J 18:1016–1018PubMed

42.

Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174PubMedCrossRef

43.

De Wever O, Mareel M (2002) Role of myofibroblasts at the invasion front. Biol Chem 383:55–67PubMedCrossRef

44.

Poulsom R, Pignatelli M, Stetler-Stevenson WG et al (1992) Stromal expression of 72 kDa type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 141:389–396PubMed

45.

Pyke C, Ralfkiaer E, Tryggvason K, Danø K (1993) Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 142:359–365PubMed

46.

Shintani Y, Wheelock MJ, Johnson KR (2006) Phosphoinositide-3 kinase-Rac1-c-Jun NH2-terminal kinase signaling mediates collagen I-induced cell scattering and up-regulation of N-cadherin expression in mouse mammary epithelial cells. Mol Biol Cell 17:2963–2975PubMedCrossRef

47.

Shintani Y, Hollingsworth MA, Wheelock MJ, Johnson KR (2006) Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH2-terminal kinase 1 and up-regulating N-cadherin expression. Cancer Res 66:11745–11753PubMedCrossRef

48.

Koenig A, Mueller C, Hasel C et al (2006) Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells. Cancer Res 66:4662–4671PubMedCrossRef

49.

Navarro P, Ruco L, Dejana E (1998) Differential localization of VE- and N-cadherins in human endothelial cells: VE-cadherin competes with N-cadherin for junctional localization. J Cell Biol 140:1475–1484PubMedCrossRef

50.

Gerhardt H, Wolburg H, Redies C (2000) N-cadherin mediates pericytic-endothelial interaction during brain angiogenesis in the chicken. Dev Dyn 218:472–479PubMedCrossRef

51.

Luo Y, Radice GL (2005) N-cadherin acts upstream of VE-cadherin in controlling vascular morphogenesis. J Cell Biol 169:29–34PubMedCrossRef

52.

Carmeliet P, Lampugnani M-G, Moons L et al (1999) Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98:147–157PubMedCrossRef

53.

Paik J-H, Skoura A, Chae S-S et al (2004) Sphingosine 1-phosphate receptor regulation of N-cadherin mediates vascular stabilization. Genes Dev 18:2392–2403PubMedCrossRef

54.

Harnden P, Shelley MD, Clements H et al (2007) The prognostic significance of perineural invasion in prostatic cancer biopsies. A systematic review. Cancer 109:13–24PubMedCrossRef

55.

Ayala GE, Wheeler TM, Shine HD et al (2001) In vitro dorsal root ganglia and human prostate cell line interaction: redefining perineural invasion in prostate cancer. Prostate 49:213–223PubMedCrossRef

56.

Ayala GE, Dai H, Ittmann M et al (2004) Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res 64:6082–6090PubMedCrossRef

57.

Takeichi M (1991) Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251:1451–1455PubMedCrossRef

58.

Tran NL, Adams DG, Vaillancourt RR, Heimark RL (2002) Signal Transduction from N-cadherin Increases Bcl-2. Regulation of the phosphatidylinositol 3-kinase/Akt pathway by homophilic adhesion and actin cytoskeletal organization. J Biol Chem 277:32905–32914PubMedCrossRef

59.

Ayala GE, Dai H, Tahir SA et al (2006) Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Res 66:5159–5164PubMedCrossRef

60.

Suyama K, Shapiro I, Guttman M, Hazan RB (2002) A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2:301–314PubMedCrossRef

61.

Weeraratna AT, Jiang Y, Hostetter G et al (2002) Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1:279–288PubMedCrossRef

62.

Rodrigues S, De Wever O, Bruyneel E et al (2007) Opposing roles of netrin-1 and the dependence receptor DCC in cancer cell invasion, tumor growth and metastasis. Oncogene 26:5615–5625PubMedCrossRef

63.

Giordano S, Corso S, Conrotto P et al (2002) The Semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol 4:720–724PubMedCrossRef

64.

Cornell RJ, Rowley D, Wheeler T et al (2003) Neuroepithelial interactions in prostate cancer are enhanced in the presence ofprostatic stroma. Urology 61:870–875PubMedCrossRef

65.

Dalton WS, Friend SH (2006) Cancer biomarkers - an invitation to the table. Science 312:1165–1168PubMedCrossRef

66.

Joensuu H, Anttonen A, Eriksson M et al (2002) Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 62:5210–5217PubMed

67.

Seidel C, Sundan A, Hjorth M et al (2000) Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95:388–392PubMed

68.

Tartour E, Mosseri V, Jouffroy T et al (2001) Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet 357:1263–1264PubMedCrossRef

69.

Witkowska AM (2005) On the role of sIL-2R measurements in rheumatoid arthritis and cancers. Mediators Inflamm 2005:121–130PubMedCrossRef

70.

Chan AOO, Lam SK, Chu KM et al (2001) Soluble E-cadherin is a valid prognostic marker in gastric carcinoma. Gut 48:808–811PubMedCrossRef

71.

Velikova G, Banks RE, Gearing A et al (1997) Circulating soluble adhesion molecules E-cadherin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in patients with gastric cancer. Br J Cancer 76:1398–1404PubMed

72.

Gofuku J, Shiozaki H, Doki Y et al (1998) Characterization of soluble E-cadherin as a disease marker in gastric cancer patients. Br J Cancer 78:1095–1101PubMed

73.

Chan AO-O, Chu K-M, Lam S-K et al (2003) Soluble E-cadherin is an independent pretherapeutic factor for long-term survival in gastric cancer. J Clin Oncol 21:2288–2293PubMedCrossRef

74.

Juhasz M, Ebert MPA, Schulz HU et al (2003) Dual role of serum soluble E-cadherin as a biological marker of metastatic development in gastric cancer. Scand J Gastroenterol 38:850–855PubMedCrossRef

75.

Chan AOO, Chu K-M, Lam SK et al (2005) Early prediction of tumor recurrence after curative resection of gastric carcinoma by measuring soluble E-cadherin. Cancer 104:740–746PubMedCrossRef

76.

Griffiths TRL, Brotherick I, Bishop RI et al (1996) Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. Br J Cancer 74:579–584PubMed

77.

Durkan GC, Brotherick I, Mellon JK (1999) The impact of transurethral resection of bladder tumour on serum levels of soluble E-cadherin. BJU Int 83:424–428PubMedCrossRef

78.

Matsumoto K, Shariat SF, Casella R et al (2003) Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol 170:2248–2252PubMedCrossRef

79.

Kuefer R, Hofer MD, Gschwend JE et al (2003) The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. Clin Cancer Res 9:6447–6452PubMed

80.

Kuefer R, Hofer MD, Zorn CSM et al (2005) Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer. Br J Cancer 92:2018–2023PubMedCrossRef

81.

Gadducci A, Ferdeghini M, Cosio S et al (1999) Preoperative serum E-cadherin assay in patients with ovarian carcinoma. Anticancer Res 19:769–772PubMed

82.

Velikova G, Banks RE, Gearing A et al (1998) Serum concentrations of soluble adhesion molecules in patients with colorectal cancer. Br J Cancer 77:1857–1863PubMed

83.

Wilmanns C, Grossmann J, Steinhauer S et al (2004) Soluble serum E-cadherin as a marker of tumour progression in colorectal cancer patients. Clin Exp Metastasis 21:75–78PubMedCrossRef

84.

Shirahama S, Furukawa F, Wakita H, Takigawa M (1996) E- and P-cadherin expression in tumor tissues and soluble E-cadherin levels in sera of patients with skin cancer. J Dermatol Sci 13:30–36PubMedCrossRef

85.

Billion K, Ibrahim H, Mauch C, Niessen CM (2006) Increased soluble E-cadherin in melanoma patients. Skin Pharmacol Physiol 19:65–70PubMedCrossRef

86.

Charalabopoulos K, Gogali A, Dalavaga Y et al (2006) The clinical significance of soluble E-cadherin in nonsmall cell lung cancer. Exp Oncol 28:83–85PubMed

87.

Banks RE, Porter WH, Whelan P et al (1995) Soluble forms of the adhesion molecule E-cadherin in urine. J Clin Pathol 48:179–180PubMedCrossRef

88.

Protheroe AS, Banks RE, Mzimba M et al (1999) Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer. Br J Cancer 80:273–278PubMedCrossRef

89.

Daraï E, Bringuier A-F, Walker-Combrouze F et al (1998) Soluble adhesion molecules in serum and cyst fluid from patients with cystic tumours of the ovary. Hum Reprod 13:2831–2835PubMedCrossRef

90.

Sundfeldt K, Ivarsson K, Rask K et al (2001) Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumours than in benign cysts. Anticancer Res 21:65–70PubMed

91.

Knudsen KA, Lin CY, Johnson KR et al (2000) Lack of correlation between serum levels of E- and P-cadherin fragments and the presence of breast cancer. Hum Pathol 31:961–965PubMedCrossRef

92.

Sulkowska M, Famulski W, Wincewicz A et al (2006) Levels of VE-cadherin increase independently of VEGF in preoperative sera of patients with colorectal cancer. Tumori 92:67–71PubMed

93.

Derycke L, De Wever O, Stove V et al (2006) Soluble N-cadherin in human biological fluids. Int J Cancer 119:2895–2900PubMedCrossRef

94.

Pittard AJ, Banks RE, Galley HF, Webster NR (1996) Soluble E-cadherin concentrations in patients with systemic inflammatory response syndrome and multiorgan dysfunction syndrome. Br J Anaesth 76:629–631PubMed

95.

Soler AP, Russo J, Russo IH, Knudsen KA (2002) Soluble fragment of P-cadherin adhesion protein found in human milk. J Cell Biochem 85:180–184PubMedCrossRef

96.

De Paul AL, Bonaterra M, Soler AP et al (2005) Soluble P-cadherin found in human semen. J Androl 26:44–47PubMed

97.

Soeki T, Tamura Y, Shinohara H et al (2004) Elevated concentration of soluble vascular endothelial cadherin is associated with coronary atherosclerosis. Circ J 68:1–5PubMedCrossRef

98.

Lafky JM, Baron AT, Cora EM et al (2005) Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole. Cancer Res 65:3059–3062PubMed

99.

Derycke LDM, Bracke ME (2004) N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int J Dev Biol 48:463–476PubMedCrossRef

100.

Zhang B, Groffen J, Heisterkamp N (2007) Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells. Leukemia 21:1189–1197PubMedCrossRef

101.

Hulit J, Suyama K, Chung S et al (2007) N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Res 67:3106–3116PubMedCrossRef

102.

Williams E, Williams G, Gour BJ et al (2000) A novel family of cyclic peptide antagonists suggests that N-cadherin specificity is determined by amino acids that flank the HAV motif. J Biol Chem 275:4007–4012PubMedCrossRef

103.

Williams G, Williams E-J, Doherty P (2002) Dimeric versions of two short N-cadherin binding motifs (HAVDI and INPISG) function as N-cadherin agonists. J Biol Chem 277:4361–4367PubMedCrossRef

104.

Mariotti A, Perotti A, Sessa C, Rüegg C (2007) N-cadherin as a therapeutic target in cancer. Expert Opin Investig Drugs 16:451–465PubMedCrossRef

105.

Tomita K, van Bokhoven A, van Leenders GJLH et al (2000) Cadherin switching in human prostate cancer progression. Cancer Res 60:3650–3654PubMed

106.

Lee DM, Kiener HP, Agarwal SK et al (2007) Cadherin-11 in synovial lining formation and pathology in arthritis. Science 315:1006–1010PubMedCrossRef

107.

Williams E-J, Williams G, Howell FV et al (2001) Identification of an N-cadherin motif that can interact with the fibroblast growth factor receptor and is required for axonal growth. J Biol Chem 276:43879–43886PubMedCrossRef

108.

Kim J-B, Islam S, Kim YJ et al (2000) N-Cadherin extracellular repeat 4 mediates epithelial to mesenchymal transition and increased motility. J Cell Biol 151:1193–1206PubMedCrossRef

109.

D’Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082–4085PubMedCrossRef

110.

Thiele A, Thormann M, Hofmann H-J et al (2000) A possible role of N-cadherin in thalidomide teratogenicity. Life Sci 67:457–461PubMedCrossRef

111.

Anderson KC (2007) Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp Hematol 35:155–162PubMedCrossRef

112.

Gupta D, Treon SP, Shima Y et al (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15:1950–1961PubMed

113.

Visentin B, Vekich JA, Sibbald BJ et al (2006) Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9:225–238PubMedCrossRef

114.

Bagnato A, Rosanò L, Spinella F et al (2004) Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res 64:1436–1443PubMedCrossRef

115.

Yang Y-a, Dukhanina O, Tang B et al (2002) Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J Clin Invest 109:1607–1615PubMed

116.

Muraoka RS, Dumont N, Ritter CA et al (2002) Blockade of TGF-ß inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 109:1551–1559PubMed

117.

Won J, Kim H, Park EJ et al (1999) Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor β receptor therapy. Cancer Res 59:1273–1277PubMed

118.

Inman GJ, Nicolás FJ, Callahan JF et al (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62:65–74PubMedCrossRef

119.

Laping NJ, Grygielko E, Mathur A et al (2002) Inhibition of transforming growth factor (TGF)-ß1-induced extracellular matrix with a novel inhibitor of the TGF-ß type I receptor kinase activity: SB-431542. Mol Pharmacol 62:58–64PubMedCrossRef

120.

Hjelmeland MD, Hjelmeland AB, Sathornsumetee S et al (2004) SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther 3:737–745PubMed

121.

Matsuyama S, Iwadate M, Kondo M et al (2003) SB-431542 and Gleevec inhibit transforming growth factor-β-induced proliferation of human osteosarcoma cells. Cancer Res 63:7791–7798PubMed

Title: Soluble cadherins as cancer biomarkers
Authors: Olivier De Wever
Lara Derycke
An Hendrix
Gert De Meerleer
François Godeau
Herman Depypere
Marc Bracke
Publication date: 01-11-2007
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 8/2007
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-007-9104-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2007

TGF-β and BMP7 interactions in tumour progression and bone metastasis

Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms

Gene arrays for diagnosis, prognosis and treatment of breast cancer metastasis

Rho GTPases: functions and association with cancer

Breast cancer progression: insights into multifaceted matrix metalloproteinases

Advances in optical imaging and novel model systems for cancer metastasis research

Keynote webinar | Spotlight on antibody–drug conjugates in cancer